Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Diurnal Group PLC

http://www.diurnal.co.uk/

Latest From Diurnal Group PLC

Asia Deal Watch: Heartseed Licenses Lead Cell Therapy Candidate To Novo Nordisk

Novo gets worldwide development and commercial rights except for Heartseed’s home market in Japan. LianBio unveils licensing partnerships with Lyra, Landos and Nanobiotix.

Deals Business Strategies

Diurnal Renames Orphan Drug As Efmody, Expecting EU-Wide Approval

New treatments for congenital adrenal hyperplasia and relapsing forms of multiple sclerosis are among five drugs recommended for pan-EU approval this month. In addition, harmonized EU advice has been issued for Celltrion’s monoclonal antibody COVID-19 treatment.

Europe Drug Review

EU Crunch Time For Diurnal’s Potentially 'Transformational' Rare Disease Drug

The European Medicines Agency is deciding on the EU marketing application for Chronocort, a life-long treatment for congenital adrenal hyperplasia.

Europe Drug Review

Asia Deal Watch: Kyongbo To Supply Ceftobiprole API For Basilea

Plus deals involving Helixmith/Wacker, Sosei Heptares/Metrion, Ono/Ribon, Asahi Kasei/Lilly, Citrine/Diurnal, Mitsubishi Tanabe/Aquestive, Immunotech/T-Cure, TRIGR/Elpiscience, Daiichi Sankyo/ViGeneron

Deals Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
  • Biotechnology
    • Drug Discovery Tools
  • Other Names / Subsidiaries
    • Diurnal Limited
UsernamePublicRestriction

Register